Zhengye Biotechnology Holding Limited(ZYBT)Earnings, Financials & Key Ratios
ZYBT•NASDAQ
$0.98
$45M mkt cap·Price updated May 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryAnimal health pharmaceuticals and vaccines
AboutZhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.Show more
- Revenue$186M-12.0%
- EBITDA$41M-41.1%
- Net Income$11M-64.0%
- EPS (Diluted)0.00
- Gross Margin48.99%-20.2%
- EBITDA Margin21.79%-33.1%
- Operating Margin8.82%-58.5%
- Net Margin6.07%-59.2%
- ROE3.27%-63.8%
- ROIC2.96%-63.8%
- Debt/Equity0.25-7.4%
- Interest Coverage4.07-60.0%
ZYBT Key Insights
Zhengye Biotechnology Holding Limited (ZYBT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 5.3%
- ✓Healthy 5Y average net margin of 14.3%
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Dividend payout exceeds 100% of earnings
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ZYBT Price & Volume
Zhengye Biotechnology Holding Limited (ZYBT) stock price & volume — 10-year historical chart
Loading chart...
ZYBT Growth Metrics
Zhengye Biotechnology Holding Limited (ZYBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-4.52%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-33.78%
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years13.19%
5 Years13.19%
3 Years12.12%
Last Year4.65%
ZYBT Peer Comparison
Zhengye Biotechnology Holding Limited (ZYBT) competitors in Animal health pharmaceuticals and vaccines — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATXG | 2.82M | 4.89 | -0.38 | -18.88% | -201.97% | -31.72% | 1.03 | |
 CLPS | 25.36M | 0.91 | -3.48 | 15.17% | -1.27% | -6.06% | 0.59 | |
 TAOP | 1.3M | 1.30 | -0.16 | -15.97% | -19.58% | -46.71% | 0.50 | |
 CNET | 1.86M | 0.70 | -0.38 | -49.52% | -33.36% | -60.34% | 0.03 | |
 AGRI | 311.84K | 0.77 | -0.02 | 316.97% | -14.4% | -159.87% | 0.24 | |
 SEED | 8.54M | 1.14 | -1.10 | -20.52% | -42.61% | |||
 HNVR | 166.82M | 23.26 | 23.26 | -3.4% | 3.76% | 0.68 | ||
 BTBT | 589.49M | 1.83 | 9.15 | 264.59% | 21.41% | 0.03 |
Compare ZYBT vs Peers
Zhengye Biotechnology Holding Limited (ZYBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZYBT Income Statement
Zhengye Biotechnology Holding Limited (ZYBT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 214.07M | 260.27M | 211.65M | 186.36M | - |
| Revenue Growth % | - | 21.58% | -18.68% | -11.95% | - |
| Cost of Goods Sold | 88.67M | 106.75M | 81.8M | 95.06M | - |
| COGS % of Revenue | 41.42% | 41.02% | 38.65% | 51.01% | - |
| Gross Profit | 125.39M▲ 0% | 153.52M▲ 22.4% | 129.85M▼ 15.4% | 91.3M▼ 29.7% | -▲ 0% |
| Gross Margin % | 58.58% | 58.98% | 61.35% | 48.99% | - |
| Gross Profit Growth % | - | 22.43% | -15.41% | -29.69% | - |
| Operating Expenses | 73.01M | 87.69M | 84.87M | 74.86M | - |
| OpEx % of Revenue | 34.11% | 33.69% | 40.1% | 40.17% | - |
| Selling, General & Admin | 58.19M | 63.56M | 66.63M | 63.84M | - |
| SG&A % of Revenue | 27.18% | 24.42% | 31.48% | 34.26% | - |
| Research & Development | 11.37M | 13.42M | 11.9M | 12.79M | - |
| R&D % of Revenue | 5.31% | 5.16% | 5.62% | 6.87% | - |
| Other Operating Expenses | 3.45M | 10.7M | 6.33M | -1.78M | - |
| Operating Income | 52.38M▲ 0% | 65.83M▲ 25.7% | 44.99M▼ 31.7% | 16.44M▼ 63.5% | -▲ 0% |
| Operating Margin % | 24.47% | 25.29% | 21.25% | 8.82% | - |
| Operating Income Growth % | - | 25.68% | -31.67% | -63.46% | - |
| EBITDA | 68.39M | 84.63M | 68.9M | 40.6M | - |
| EBITDA Margin % | 31.95% | 32.52% | 32.55% | 21.79% | - |
| EBITDA Growth % | - | 23.74% | -18.59% | -41.07% | - |
| D&A (Non-Cash Add-back) | 16.01M | 18.8M | 23.91M | 24.16M | - |
| EBIT | 54.11M | 66.75M | 48.19M | 18.44M | - |
| Net Interest Income | -934K | -2.73M | -4.11M | -3.81M | - |
| Interest Income | 112K | 114K | 312K | 231K | - |
| Interest Expense | 1.05M | 2.84M | 4.42M | 4.04M | - |
| Other Income/Expense | 683K | -1.92M | -1.22M | -2.04M | - |
| Pretax Income | 53.07M▲ 0% | 63.91M▲ 20.4% | 43.76M▼ 31.5% | 14.39M▼ 67.1% | -▲ 0% |
| Pretax Margin % | 24.79% | 24.56% | 20.68% | 7.72% | - |
| Income Tax | 6.6M | 8.17M | 6.25M | 924K | - |
| Effective Tax Rate % | 12.44% | 12.79% | 14.29% | 6.42% | - |
| Net Income | 38.96M▲ 0% | 46.73M▲ 20.0% | 31.46M▼ 32.7% | 11.31M▼ 64.0% | -▲ 0% |
| Net Margin % | 18.2% | 17.96% | 14.86% | 6.07% | - |
| Net Income Growth % | - | 19.96% | -32.69% | -64.04% | - |
| Net Income (Continuing) | 46.47M | 55.74M | 37.51M | 13.47M | - |
| Discontinued Operations | 0 | 0 | 0 | 0 | - |
| Minority Interest | 51.36M | 60.37M | 66.42M | 68.58M | - |
| EPS (Diluted) | 0.00▲ 0% | 0.00▲ 0% | 0.00▲ 0% | 0.00▲ 0% | -▲ 0% |
| EPS Growth % | - | - | - | - | - |
| EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Diluted Shares Outstanding | 0 | 0 | 0 | 0 | 45.67M |
| Basic Shares Outstanding | 0 | 0 | 0 | 0 | 45.67M |
| Dividend Payout Ratio | 28.36% | 45.84% | 125.42% | 141.66% | - |
ZYBT Balance Sheet
Zhengye Biotechnology Holding Limited (ZYBT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 164.94M | 214.31M | 205.59M | 177.57M | - |
| Cash & Short-Term Investments | 6.28M | 9.75M | 16.3M | 20.04M | 18.6M |
| Cash Only | 6.28M | 9.75M | 15.07M | 18.6M | 18.6M |
| Short-Term Investments | 0 | 0 | 1.22M | 1.43M | - |
| Accounts Receivable | 102.19M | 134.25M | 99.42M | 88.52M | - |
| Days Sales Outstanding | 174.24 | 188.27 | 171.46 | 173.37 | - |
| Inventory | 43.62M | 55.42M | 58.3M | 58.22M | - |
| Days Inventory Outstanding | 179.56 | 189.51 | 260.15 | 223.54 | - |
| Other Current Assets | 11.14M | 12.46M | 24.03M | 2K | - |
| Total Non-Current Assets | 280.33M | 305.37M | 294.3M | 315.68M | - |
| Property, Plant & Equipment | 255.12M | 283.67M | 271.5M | 255.16M | - |
| Fixed Asset Turnover | 0.84x | 0.92x | 0.78x | 0.73x | - |
| Goodwill | 0 | 0 | 0 | 0 | - |
| Intangible Assets | 12.05M | 19.46M | 16.3M | 22.78M | - |
| Long-Term Investments | 0 | 0 | 0 | 0 | - |
| Other Non-Current Assets | 13.17M | 2.23M | 6.5M | 26.75M | - |
| Total Assets | 445.28M▲ 0% | 519.67M▲ 16.7% | 499.89M▼ 3.8% | 493.25M▼ 1.3% | 493.25M▲ 0% |
| Asset Turnover | 0.48x | 0.50x | 0.42x | 0.38x | - |
| Asset Growth % | - | 16.71% | -3.81% | -1.33% | - |
| Total Current Liabilities | 125.63M | 152.23M | 150.23M | 135.91M | - |
| Accounts Payable | 77.57M | 79.28M | 45.66M | 42.96M | - |
| Days Payables Outstanding | 319.28 | 271.06 | 203.75 | 164.95 | - |
| Short-Term Debt | 30M | 54.89M | 79.86M | 81.63M | - |
| Deferred Revenue (Current) | 4.28M | 4.7M | 3.98M | 3.69M | - |
| Other Current Liabilities | 0 | 0 | 0 | 3.28M | - |
| Current Ratio | 1.31x | 1.41x | 1.37x | 1.31x | 1.31x |
| Quick Ratio | 0.97x | 1.04x | 0.98x | 0.88x | 0.88x |
| Cash Conversion Cycle | 34.52 | 106.72 | 227.86 | 231.97 | - |
| Total Non-Current Liabilities | 816K | 10.58M | 10.38M | 4.8M | - |
| Long-Term Debt | 0 | 9.99M | 9.99M | 4.8M | - |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | - |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | - |
| Other Non-Current Liabilities | 816K | 590K | 393K | 0 | - |
| Total Liabilities | 126.44M | 162.81M | 160.62M | 140.71M | - |
| Total Debt | 30M | 64.88M | 89.85M | 86.43M | 86.43M |
| Net Debt | 23.72M | 55.13M | 74.78M | 67.83M | 67.83M |
| Debt / Equity | 0.09x | 0.18x | 0.26x | 0.25x | 0.25x |
| Debt / EBITDA | 0.44x | 0.77x | 1.30x | 2.13x | - |
| Net Debt / EBITDA | 0.35x | 0.65x | 1.09x | 1.67x | 1.67x |
| Interest Coverage | 50.08x | 23.19x | 10.17x | 4.07x | - |
| Total Equity | 318.84M▲ 0% | 356.87M▲ 11.9% | 339.27M▼ 4.9% | 352.54M▲ 3.9% | 352.54M▲ 0% |
| Equity Growth % | - | 11.93% | -4.93% | 3.91% | - |
| Book Value per Share | - | - | - | 7.72 | 7.72 |
| Total Shareholders' Equity | 267.47M | 296.5M | 272.85M | 283.96M | 352.54M |
| Common Stock | 8K | 8K | 8K | 8K | - |
| Retained Earnings | 42.33M | 65.77M | 38.38M | 48.15M | - |
| Treasury Stock | 0 | 0 | 0 | 0 | - |
| Accumulated OCI | 21.99M | 27.57M | 31.31M | 32.65M | - |
| Minority Interest | 51.36M | 60.37M | 66.42M | 68.58M | - |
ZYBT Cash Flow Statement
Zhengye Biotechnology Holding Limited (ZYBT) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | 31.81M | 17.34M | 48.18M | 41.05M | 41.05M |
| Operating CF Margin % | 14.86% | 6.66% | 22.77% | 22.03% | - |
| Operating CF Growth % | - | -45.5% | 177.96% | -14.81% | - |
| Net Income | 46.47M | 55.74M | 37.51M | 13.47M | - |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | - |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | - |
| Deferred Taxes | -358K | -1.09M | 758K | 924K | - |
| Other Non-Cash Items | 3.4M | 10.7M | 6.5M | 3.47M | - |
| Working Capital Changes | -33.71M | -66.82M | -20.49M | -977K | - |
| Change in Receivables | -40.91M | -47.38M | 38.05M | 11.31M | - |
| Change in Inventory | -12.34M | -12.32M | -12.9M | -5.88M | - |
| Change in Payables | 17.63M | -9.67M | -35.61M | -404K | - |
| Cash from Investing | -26.27M | -27.33M | -11.77M | -27.66M | - |
| Capital Expenditures | -19.06M | -27.33M | -7.4M | -13.59M | - |
| CapEx % of Revenue | 8.9% | 10.5% | 3.49% | 7.29% | - |
| Acquisitions | 0 | 0 | 0 | 0 | - |
| Investments | - | - | - | - | - |
| Other Investing | -7.21M | 0 | -3.15M | -14.08M | - |
| Cash from Financing | -3.05M | 13.46M | -18.98M | -22.13M | - |
| Debt Issued (Net) | 8M | 34.88M | 24.97M | -2.74M | - |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | - |
| Dividends Paid | -11.05M | -21.43M | -39.45M | -16.02M | - |
| Share Repurchases | 0 | 0 | 0 | 0 | - |
| Other Financing | 0 | 0 | -4.5M | -3.37M | - |
| Net Change in Cash | 2.49M▲ 0% | 3.46M▲ 39.1% | 17.44M▲ 403.8% | -8.58M▼ 149.2% | -▲ 0% |
| Free Cash Flow | 5.41M▲ 0% | -9.99M▼ 284.7% | 36.58M▲ 466.1% | 13.27M▼ 63.7% | -▲ 0% |
| FCF Margin % | 2.53% | -3.84% | 17.29% | 7.12% | - |
| FCF Growth % | - | -284.75% | 466.1% | -63.72% | - |
| FCF per Share | - | - | - | 0.29 | 0.29 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.37x | 1.53x | 3.63x | - |
| Interest Paid | 1.05M | 2.84M | 4.42M | 3.98M | - |
| Taxes Paid | 6.99M | 8.48M | 10.49M | 116K | - |
ZYBT Key Ratios
Zhengye Biotechnology Holding Limited (ZYBT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | 13.83% | 9.04% | 3.27% | - |
| Return on Invested Capital (ROIC) | 13.09% | 8.17% | 2.96% | 2.96% |
| Gross Margin | 58.98% | 61.35% | 48.99% | - |
| Net Margin | 17.96% | 14.86% | 6.07% | - |
| Debt / Equity | 0.18x | 0.26x | 0.25x | 0.25x |
| Interest Coverage | 23.19x | 10.17x | 4.07x | - |
| FCF Conversion | 0.37x | 1.53x | 3.63x | - |
| Revenue Growth | 21.58% | -18.68% | -11.95% | - |
ZYBT Frequently Asked Questions
Zhengye Biotechnology Holding Limited (ZYBT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zhengye Biotechnology Holding Limited (ZYBT) reported $186.4M in revenue for fiscal year 2024. This represents a 13% decrease from $214.1M in 2021.
Zhengye Biotechnology Holding Limited (ZYBT) saw revenue decline by 12.0% over the past year.
Yes, Zhengye Biotechnology Holding Limited (ZYBT) is profitable, generating $11.3M in net income for fiscal year 2024 (6.1% net margin).
Dividend & Returns
Yes, Zhengye Biotechnology Holding Limited (ZYBT) pays a dividend with a yield of 5.27%. This makes it attractive for income-focused investors.
Zhengye Biotechnology Holding Limited (ZYBT) has a return on equity (ROE) of 3.3%. This is below average, suggesting room for improvement.
Zhengye Biotechnology Holding Limited (ZYBT) generated $13.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ZYBT
Zhengye Biotechnology Holding Limited (ZYBT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates